International Business Times—August 9, 2016
International Business Times reporter Seerat Chabba writes on Mesoblast’s recent announcement that their experiments as part of a stem-cell treatment has led to significant improvements of symptoms and disease in rheumatoid arthritis patients who were unable to get relief through widely used biotech medicines.
"The safety and efficacy results of this study are very encouraging and suggest that Mesoblast’s cell therapy has the potential to fill the major unmet medical need of the biologic refractory RA population, where agents that provide consistent durable effects without the risk of opportunistic infections or malignancies are sorely needed," said Allan Gibofsky, MD, a rheumatologist at Hospital for Special Surgery.
To read the full article, visit IBTimes.com.
Additional coverage:
212.606.1197
mediarelations@hss.edu